Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
Study data from University of Rochester update understanding of vaccines
March 25th, 2009
Data detailed in 'An adenoviral vector-based mucosal vaccine is effective in protection against botulism' have been presented. According to a study from the United States, "A replication-incompetent adenoviral vector encoding the heavy chain C-fragment (H(C)50) of botulinum neurotoxin type C (BoNT/C) was evaluated as a mucosal vaccine against botulism in a mouse model. Single intranasal inoculation of the adenoviral vector elicited a high level of H(C)50-specific IgG, IgG1 and IgG2a in sera and IgA in mucosal secretions as early as 2 weeks after vaccination." "The antigen-specific serum antibodies were maintained at a high level at least until the 27th week. Immune sera...
Source: Vaccine Weekly (2009-03-25)
|
